Wedge Capital Management L L P NC Purchases 185 Shares of Hologic, Inc. (NASDAQ:HOLX)

Wedge Capital Management L L P NC boosted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 457,039 shares of the medical equipment provider’s stock after acquiring an additional 185 shares during the quarter. Wedge Capital Management L L P NC owned 0.20% of Hologic worth $32,948,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Federated Hermes Inc. acquired a new stake in Hologic in the 2nd quarter valued at about $246,000. Envestnet Asset Management Inc. lifted its position in shares of Hologic by 3.6% in the second quarter. Envestnet Asset Management Inc. now owns 361,271 shares of the medical equipment provider’s stock valued at $26,824,000 after buying an additional 12,671 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Hologic by 5.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider’s stock worth $172,780,000 after acquiring an additional 124,739 shares during the period. Edgestream Partners L.P. acquired a new position in shares of Hologic during the 2nd quarter worth approximately $1,696,000. Finally, Mercer Global Advisors Inc. ADV raised its stake in Hologic by 31.1% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 72,220 shares of the medical equipment provider’s stock valued at $5,362,000 after acquiring an additional 17,130 shares during the period. Institutional investors own 94.73% of the company’s stock.

Insider Buying and Selling

In other news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.75% of the stock is currently owned by corporate insiders.

Hologic Trading Down 0.3 %

Shares of HOLX opened at $69.73 on Friday. The firm has a market cap of $15.82 billion, a price-to-earnings ratio of 20.94, a PEG ratio of 2.44 and a beta of 0.97. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. Hologic, Inc. has a 52-week low of $68.61 and a 52-week high of $84.67. The business’s fifty day moving average is $74.84 and its 200-day moving average is $78.34.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the business posted $0.89 earnings per share. Equities analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

HOLX has been the topic of several research reports. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Wolfe Research initiated coverage on shares of Hologic in a report on Friday, December 13th. They issued a “peer perform” rating on the stock. Jefferies Financial Group began coverage on Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price objective for the company. Needham & Company LLC restated a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Monday, January 13th. Finally, Mizuho dropped their target price on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th. Seven analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $88.92.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.